MARKET

SAGE

SAGE

Sage Therapeutic
NASDAQ
6.86
-0.31
-4.32%
Closed 19:48 05/06 EDT
OPEN
7.13
PREV CLOSE
7.17
HIGH
7.14
LOW
6.83
VOLUME
1.57M
TURNOVER
--
52 WEEK HIGH
14.31
52 WEEK LOW
4.620
MARKET CAP
429.58M
P/E (TTM)
-1.1830
1D
5D
1M
3M
1Y
5Y
1D
SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial
TipRanks · 1d ago
Weekly Report: what happened at SAGE last week (0428-0502)?
Weekly Report · 1d ago
BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut
NASDAQ · 5d ago
SAGE Therapeutics: Hold Rating Maintained Amid Steady Growth and Strategic Uncertainties
TipRanks · 6d ago
Sage Therapeutics’ Earnings Call Highlights Growth and Uncertainty
TipRanks · 6d ago
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y
NASDAQ · 6d ago
Wedbush Remains a Hold on SAGE Therapeutics (SAGE)
TipRanks · 6d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (ATRC), SAGE Therapeutics (SAGE) and Repligen (RGEN)
TipRanks · 6d ago
More
About SAGE
More
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. It is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817.
Recently
Symbol
Price
%Change

Webull offers SAGE Therapeutics Inc stock information, including NASDAQ: SAGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAGE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SAGE stock methods without spending real money on the virtual paper trading platform.